Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Jan 15, 2019

SELL
$30.84 - $49.51 $503,031 - $807,557
-16,311 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$42.7 - $56.55 $17,507 - $23,185
410 Added 2.58%
16,311 $821,000
Q2 2018

Aug 06, 2018

BUY
$44.1 - $59.85 $701,234 - $951,674
15,901 New
15,901 $952,000

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.98B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Navellier & Associates Inc Portfolio

Follow Navellier & Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Navellier & Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Navellier & Associates Inc with notifications on news.